These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2681442)

  • 1. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
    Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
    J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-interferon antibody in chronic hepatitis C].
    Arai K; Shindo M; Okuno T
    Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
    Antonelli G; Currenti M; Turriziani O; Dianzani F
    J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
    Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
    Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal antigenicity of intron A in human recipients demonstrated by three analytical methods.
    Jacobs SJ; Sullivan LM; Salfi M; Grossberg H; Spiegel RJ; Leibowitz PJ; Oden EM; Kelsey DK; Treuhaft MW
    J Biol Response Mod; 1988 Oct; 7(5):447-56. PubMed ID: 3183684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
    Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
    J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
    Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
    Weck PK; Leventhal BG; Brand C; Finter NB
    J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
    Prümmer O
    Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis.
    Craxi A; Di Marco V; Volpes R; Palazzo U
    Hepatogastroenterology; 1988 Dec; 35(6):304-5. PubMed ID: 3063647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.
    Antonelli G; Giannelli G; Currenti M; Simeoni E; Del Vecchio S; Maggi F; Pistello M; Roffi L; Pastore G; Chemello L; Dianzani F
    Clin Exp Immunol; 1996 Jun; 104(3):384-7. PubMed ID: 9099919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.